Title
Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer.

Permalink
https://escholarship.org/uc/item/5v02r72r

Journal
Oncotarget, 8(1)

ISSN
1949-2553

Authors
Arnold Egloff, Shanna A Du, Liping Loomans, Holli A et al.

Publication Date
2017

DOI
10.18632/oncotarget.13546

Peer reviewed
Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer

Shanna A. Arnold Egloff, Liping Du, Holli A. Loomans, Alina Starchenko, Pei-Fang Su, Tatiana Ketova, Paul B. Knoll, Jifeng Wang, Ahmed Q. Haddad, Oluwole Fadare, Justin M. Cates, Yair Lotan, Yu Shyr, Peter E. Clark, Andries Zijlstra

1Department of Veterans Affairs, Nashville, TN, USA
2Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA
3Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN, USA
4Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA
5Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN, USA
6Department of Statistics, National Cheng Kung University, Taiwan
7Meharry Medical College, Nashville, TN, USA
8Department of Urology, The Fifth People’s Hospital of Shanghai, Shanghai, China
9Department of Urology, The University of Louisville, Louisville, KY, USA
10Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX, USA
11University of California San Diego, La Jolla, CA, USA
12Vanderbilt Ingram-Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA
13Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA

Correspondence to: Andries Zijlstra, email: Andries.Zijlstra@Vanderbilt.Edu

Keywords: ALCAM, bladder cancer, transitional cell carcinoma, urothelial cell carcinoma, metastasis

Received: July 06, 2016 Accepted: October 19, 2016 Published: November 24, 2016

ABSTRACT

Proteins involved in tumor cell migration can potentially serve as markers of invasive disease. Activated Leukocyte Cell Adhesion Molecule (ALCAM) promotes adhesion, while shedding of its extracellular domain is associated with migration. We hypothesized that shed ALCAM in biofluids could be predictive of progressive disease. ALCAM expression in tumor \((n = 198)\) and shedding in biofluids \((n = 120)\) were measured in two separate VUMC bladder cancer cystectomy cohorts by immunofluorescence and enzyme-linked immunosorbent assay, respectively. The primary outcome measure was accuracy of predicting 3-year overall survival (OS) with shed ALCAM compared to standard clinical indicators alone, assessed by multivariable Cox regression and concordance-indices. Validation was performed by internal bootstrap, a cohort from a second institution \((n = 64)\), and treatment of missing data with multiple-imputation. While ALCAM mRNA expression was unchanged, histological detection of ALCAM decreased with increasing stage \((P = 0.004)\). Importantly, urine ALCAM was elevated 17.0-fold \((P < 0.0001)\) above non-cancer controls, correlated positively with tumor stage \((P = 0.018)\), was an independent predictor of OS after adjusting for age, tumor stage, lymph-node status, and hematuria \((HR, 1.46; 95\% CI, 1.03–2.06; P = 0.002)\), and improved prediction of OS by 3.3% \((\text{concordance-index, 78.5\% vs. 75.2\%})\). Urine ALCAM remained an independent predictor of OS after accounting for treatment with Bacillus Calmette-Guerin, carcinoma in situ, lymph-node dissection, lymphovascular invasion, urine creatinine, and adjuvant chemotherapy \((HR, 1.10; 95\% CI, 1.02–1.19; P = 0.011)\). In conclusion, shed ALCAM may be a novel...
INTRODUCTION

Bladder cancer (BCa) is the 9th most common cancer world-wide [1] and 4th most common in men in the USA with an estimated 74,000 new cases in 2015 [2]. Approximately 20–30% of BCa is diagnosed as muscle invasive (MIBC) while 10–30% of patients with non-muscle invasive BCa (NMIBC) progress to invasive disease [3, 4]. While surgical resection of the bladder (cystectomy) can be curative, approximately 50% of cystectomy patients recur with metastases within two years [5]. The risk of progression and recurrence necessitates frequent follow-up, invasive monitoring, and repeated clinical interventions, which decreases quality of life and makes lifelong management of BCa more costly than any other cancer [6]. Moreover, despite proven survival benefit, neoadjuvant chemotherapy is under-utilized in this aging patient population with multiple comorbidities [7, 8]. Prognostic indicators could identify patients likely to benefit from aggressive intervention and improve patient care but there are currently no accurate, non-invasive ways to predict recurrence and monitor treatment response.

Accessibility makes fluid-based biomarkers attractive candidates for the diagnosis and prognosis of BCa [9]. Unfortunately, only a small proportion of fluid-based biomarkers have been investigated for prognostic significance in BCa, with the majority of studies focused on diagnostics [10, 11]. A recent multiplatform genomic analysis highlights the molecular heterogeneity of bladder cancer [12] and underscores the diversity of oncogenic mechanisms that can drive bladder cancer. However, post-translational modifications that universally support malignant progression, such as proteolytic products of cell motility, are promising biomarkers that may act as global predictors of patient outcome regardless of the underlying genetics [13]. Activated Leukocyte Cell Adhesion Molecule (ALCAM) is a cell surface protein capable of homotypic cell-cell adhesion [14–17], the disruption of which, contributes to both normal cell migration and the metastatic dissemination of tumor cells [18, 19]. ALCAM-mediated adhesion is disrupted when its ectodomain is shed by ADAM17 from the surface of tumor cells during malignant transformation [20–22]. Consequently, ALCAM shedding is a molecular indicator of a cellular activity that will ultimately present itself pathologically as invasive and/or disseminated disease. Indeed, we have recently demonstrated that, through preclinical studies of prostate cancer and clinical correlation in colorectal cancer, ALCAM contributes directly to cancer metastasis [22] and histological detection of intra-tumoral ALCAM shedding is prognostic of disease-specific survival in stage II disease [23].

ALCAM has significant potential as a fluid-based biomarker because the shed ectodomain of ALCAM is released into adjacent biofluids. While elevated serum levels of ALCAM have been reported for several non-urothelial neoplasms [20, 24–28], high baseline levels of circulating ALCAM prevent its global implementation as a blood-based biomarker. However, studies of ALCAM in ascites fluid from patients with ovarian carcinomatosis suggest ALCAM in tumor-adjacent fluids, other than blood, could predict outcome [23, 24]. In the bladder, ALCAM expression is restricted to the umbrella cells and several layers of the urothelium, which are in direct contact with the urine. Therefore, we hypothesized that elevated levels of urinary ALCAM would be indicative of invasive tumor progression and, thus, serve as a prognostic biomarker in BCa. Using retrospective cohort studies, we compared the ability of ALCAM gene expression (mRNA), tissue expression (protein), and shedding (blood and urine) to predict overall survival in BCa. This is the first study to provide a multi-level assessment of ALCAM prognostication in cancer and definitively show that it is post-translational processing of ALCAM, defined as ALCAM “shedding”, that is most predictive of patient outcome.

RESULTS

ALCAM gene expression

Analysis of ALCAM mRNA expression was performed on four independent bladder cancer cohorts available as GEO datasets at NCBI (GSE31684, n = 93; GSE48276, n = 126; GSE13507, n = 176; GSE3167, n = 46) [29–32]. A comparison of non-muscle invasive (NMIBC) and muscle invasive (MIBC) bladder cancer revealed that ALCAM expression is not significantly altered during BCa progression to invasive disease (Figure 1A).

To further determine if ALCAM mRNA expression correlated with outcome in BCa, we performed a detailed statistical analysis of the GSE31684 dataset [32]. ALCAM mRNA expression did not correlate with tumor stage (Kruskal-Wallis (K-W), P = 0.722; Jonckheere-Terpstra test for trend (J-T), P = 0.610; Figure 1B), nor did it significantly stratify patient outcome of overall survival when dichotomized around the median log2 mRNA level of 10.4 (Log-rank, P = 0.325; Hazards Ratio (HR), 1.25; 95% Confidence Interval (CI), 0.75–2.07; Figure 1C). Furthermore, multivariable Cox regression analysis reveals that ALCAM gene expression fails to reach significance as an independent predictor of 3-year overall survival after adjusting for available covariates including age, gender and tumor stage (Table 1 Top; adjusted HR, 1.26; 95% CI, 0.94–1.68; p = 0.118). Since ALCAM mRNA levels remain unaltered during tumor progression in four independent patient cohorts and fail to predict overall survival by
Table 1: Assessment of ALCAM mRNA and protein expression as a predictor in a multivariable Cox regression analysis of 3-year overall survival in bladder cancer

| Variable                | Hazard Ratio | 95.0% CI   | Significance | Bootstrap Significance |
|-------------------------|--------------|------------|--------------|-----------------------|
| Age (Years)             | 1.01a        | 0.98–1.04  | 0.404        | 0.384                 |
| Gender                  | 1.32a        | 0.70–2.48  | 0.396        | 0.383                 |
| Tumor Stage             | 2.46a        | 1.69–3.58  | < 0.0001     | 0.001                 |
| ALCAM Log2 mRNA         | 1.26a        | 0.94–1.68  | 0.118        | 0.107                 |
| Age (Years)             | 1.03a        | 1.01–1.05  | 0.01         | 0.024                 |
| Gender                  | 0.78         | 0.50–1.21  | 0.265        | 0.304                 |
| Tumor Stage             | 1.30a        | 1.12–1.50  | 0.001        | 0.001                 |
| N Stage                 | 1.42         | 1.10–1.82  | 0.006        | 0.017                 |
| ALCAM (% Thresholded Area) | 1.00a      | 0.99–1.02  | 0.843        | 0.792                 |

Assessment of ALCAM mRNA (top) and protein (bottom) expression as a predictor of 3-year overall survival by multivariable Cox regression analysis. The mRNA expression cohort is a publicly available dataset at NCBI Gene Expression Omnibus (GEO) [GSE31684] [32]. The ALCAM protein expression was measured by fluorescence intensity (% thresholded area) in the VUMC bladder cancer TMA cohort as described in Table 2. Hazard Ratio is the adjusted hazards ratio for every 1 unit increase such as 1 year or 1%. CI, confidence interval. Bootstrap significance is two-tailed with 1000 iterations and a Mersenne twister of 2,000,000.

Figure 1: Correlation of ALCAM mRNA with tumor progression and overall survival in bladder cancer. (A) Gene expression analyses performed on four independent bladder cancer cohorts, GSE31684 (n = 93), GSE48276 (n = 126), GSE13507 (n = 176), and GSE3167 (n = 46), available as GEO datasets on NCBI Gene Expression Omnibus comparing Log2 mRNA ALCAM levels of non-muscle invasive (NMIBC) and muscle invasive (MIBC) bladder cancer [29–32]. Mean and 95% confidence intervals displayed. (B–C) Analysis of the GSE31684 dataset for ALCAM Log2 mRNA correlation with tumor stage (B) and overall survival (C). (B) Mean and 95% confidence intervals displayed. K-W, Kruskal-Wallis test. J-T, Jonckheere-Terpstra test for trend. (C) Kaplan-Meier curves and Log-rank test for significance of ALCAM dichotomized high/low around the median Log2 mRNA level (10.4). HR, Hazard Ratio. CI, Confidence Interval.
univariable and multivariable analyses, we conclude that ALCAM gene expression is not a viable biomarker for BCa prognosis.

ALCAM protein expression

Post-translational proteolytic processing of ALCAM can create a disparity between gene expression and the availability of ALCAM protein. Indeed, ALCAM protein levels frequently fail to correlate with gene transcription [33]. In addition, histological detection of ALCAM has been shown to correlate with disease progression and patient outcome in several non-urothelial cancers [26, 27, 33–38].

To determine if protein expression of ALCAM in BCa correlates with tumor stage and/or patient outcome, we performed immunofluorescence staining on tissue microarrays (TMAs) constructed of high-grade BCa specimens collected during cystectomy (Table 2) as described in the methods. The final readout for ALCAM was a continuous variable defined as the area within the region of interest (epithelium) that was above background (% thresholded area). In normal bladder, ALCAM protein expression was confined to the urothelium (Figure 2A, Normal). In non-invasive carcinoma in situ, the expansion of the urothelium led to an increase in ALCAM positive cells with no increase in signal intensity (Figure 2A, CIS). However, concomitant with the appearance of an invasive phenotype, ALCAM detection and fluorescence intensity diminished in the progression from pT1 to pT4 (Figure 2A).

Since each patient had multiple cores representing several pathological stages and, thus, had non-independent samples, the correlation of the mean ALCAM intensity score with pathological core stage was analyzed with generalized estimating equations (GEE) ordinal logistic regression and Kendall’s rank correlation (K) (n = 481). Based on these analyses, ALCAM was significantly and inversely correlated with core stage, demonstrating a loss of ALCAM detection with advanced stage (K, τ = −0.16; p = 0.004; GEE OR, 1.04; 95% CI, 1.03–1.05; p < 0.0001; Figure 2B). In other words, there is a 4% increased odds of higher stage with every 1% decrease in ALCAM thresholded area. However, subsequent overall survival analysis performed using only invasive core values (n = 198) revealed that ALCAM expression failed to correlate with overall survival when percent thresholded area was dichotomized around the mean of 6.66% (Log-Rank, P = 0.413; HR, 1.18; 95% CI, 0.79–1.76; Figure 2C). Most importantly, ALCAM protein expression was not a significant predictor of overall survival when treated as a continuous covariate and adjusted for age, gender, tumor stage and lymph-node status by multivariable Cox regression analysis (Table 1 Bottom; adjusted HR, 1.00; 95% CI, 0.99–1.02; p = 0.843). These observations demonstrate that, in spite of a strong correlation between ALCAM protein detection and tumor stage, ALCAM expression fails to independently correlate with or predict patient outcome.

ALCAM shedding

While the detection of ALCAM protein within the tumor tissue is reduced with disease progression, such a trend was not observed in gene expression. Since immunofluorescence staining for ALCAM was performed with an antibody against the extracellular domain, we suspected that the loss of ALCAM in BCa tissue was likely due to proteolytic shedding of the ectodomain [20, 21]. Consequently, we hypothesized that ALCAM shed by malignant urothelium should be detectable in adjacent biofluids such as blood and urine (Figure 3A).

We first wanted to determine if ALCAM is detectable in biofluid and, if so, verify that it is, indeed, shed ALCAM and not just intact ALCAM derived from cellular debris or exosomes. Not only was ALCAM detectable, immunoblots of urine from patients with bladder cancer as well as, from tumor cell lysates and conditioned media, reveal two pieces of evidence verifying biofluid ALCAM is actually proteolytically cleaved, shed ALCAM (Figure 3B). First, there is a downward shift in the size of ALCAM detected in conditioned media and urine compared to that detected in lysate (MOG/07; Figure 3B, Left). Second, the monoclonal antibody, 1G3A, that is against the intracellular domain of ALCAM can only detect ALCAM in the cell lysate, indicating that ALCAM in the tumor cell conditioned media and urine is lacking this intracellular domain (1G3A; Figure 3B, Right).

Shed ALCAM levels in serum and urine

We next analyzed serum and urine ALCAM levels by ELISA from patients in four distinct biofluid cohorts including: 1) patients undergoing surgery but with no cancer (Normal Controls), 2) patients with inflammatory diseases (Inflammation), 3) patients with non-bladder malignancies (General Cancer) and 4) patients with high-grade bladder cancer (BCa). Analysis of serum ALCAM revealed that it was moderately elevated in BCa patients compared to Normal Controls (Figure 3C; 1.3-fold, P < 0.0001). In contrast, the level of ALCAM in urine from BCa patients was dramatically elevated when compared to Normal Controls (Figure 3D; 17.0-fold, P < 0.0001). Urinary ALCAM levels were also measured for patients with inflammatory diseases or other cancers to confirm that the significant elevation of urine ALCAM was specific to the presence of BCa. These non-BCa urines did show elevated levels of ALCAM when compared to normal controls (Figure 3D; 5.6 and 6.6-fold; P = 0.0183 and P < 0.0001) but still contained significantly less ALCAM than the BCa urines (Figure 3C; 3.0 and 2.5-fold; both P < 0.0001).

Quality control

Quality control assays were performed to ensure that a commercially available ELISA test of ALCAM was sufficiently repeatable (i.e. reproducible within the same
Table 2: Bladder cancer TMA ALCAM expression cohort descriptors and frequencies

|                                | N   | Quartiles             | Mean ± SD  |
|--------------------------------|-----|-----------------------|------------|
| Age (Years)                    | 198 | 59, 67, 73            | 66 ± 11    |
| ALCAM % Thresholded Area (IF)  | 198 | 0.33, 1.64, 6.50      | 6.56 ± 11.69 |
| Follow-up (Months)             | 198 | 9.3, 25.4, 54.0       | 33.4 ± 27.3 |
| Time to Death 3 Years (Months) | 198 | 4.2, 12.6, 18.7       | 12.4 ± 9.0  |
| Time to Death (Months)         | 198 | 5.5, 14.1, 25.5       | 18.4 ± 16.4 |

|                                | N   | Percent   | Frequency |
|--------------------------------|-----|-----------|-----------|
| Gender                         | 198 | 21.2%     | 42        |
| Female                         |     | 78.8%     | 156       |
| Male                           |     |           |           |
| Race                           | 198 | 93.4%     | 185       |
| White                          |     | 4.5%      | 9         |
| Black                          |     | 2.0%      | 4         |
| Other                          |     |           |           |
| Death (Full Follow-up)         | 198 | 34.3%     | 68        |
| 0                              |     | 65.7%     | 130       |
| Death (3 years)                | 198 | 44.9%     | 89        |
| 0                              |     | 55.1%     | 109       |
| Pathological Tumor Stage       | 198 | 0.5%      | 1         |
| pTa                            |     | 0.5%      | 1         |
| pTis                           |     | 10.6%     | 21        |
| pT1                            |     | 17.2%     | 34        |
| pT2a                           |     | 18.7%     | 37        |
| pT2b                           |     | 21.2%     | 42        |
| pT3a                           |     | 15.7%     | 31        |
| pT3b                           |     | 15.2%     | 30        |
| pT4a                           |     | 0.5%      | 1         |
| pT4b                           |     |           |           |
| N Stage                        | 198 | 71.2%     | 141       |
| N0                             |     | 10.6%     | 21        |
| N1                             |     | 18.2%     | 36        |
| Core Stage                     | 481 | 29.3%     | 141       |
| Normal                         |     | 5.6%      | 27        |
| pTa                            |     | 24.3%     | 117       |
| pTis                           |     | 4.4%      | 21        |
| pT1                            |     | 14.8%     | 71        |
| pT2                            |     | 15.2%     | 73        |
| pT3                            |     | 6.4%      | 31        |

Description of the bladder cancer TMA patient cohort used for prognostic assessment of ALCAM expression by immunohistochemistry and immunofluorescence. There are 301 patients represented in the TMA with 657 cores total. Cores were classified by a pathologist as normal, pTis, pTa or “invasive” with each patient having multiple stages represented in
Urinary ALCAM measurements were not significantly influenced by freeze-thaw (Supplementary Figure S1A), collection method (Supplementary Figure S1B; foley-derived vs. clean catch urine), or assay variation (Supplementary Figure S1C and S1D; 4–12% inter-assay variation).

**Shed ALCAM and univariable overall survival correlation**

Since both serum and urine ALCAM concentrations were elevated in BCa, we set out to determine if either correlated with tumor stage and/or patient outcome using the VUMC cohort (Table 3, \( n = 120 \)). Serum ALCAM levels did not show correlation with pathological tumor stage (Figure 3E; Kruskal-Wallis (K-W), \( P = 0.595 \); Jonckheere-Terpstra test for trend (J-T), \( P = 0.943 \)). Urine ALCAM levels were not significantly different between tumor stages but did show a significant positive trend (Figure 3F; K-W, \( P = 0.058 \); J-T, \( P = 0.018 \)), suggesting that ALCAM shedding increases with invasive progression. Next, Kaplan-Meier curves for overall survival were plotted for tumor stage, urine ALCAM and serum ALCAM (Figure 4A–4C). As expected, advanced tumor stage (≥ pT3, high stage) significantly correlated with decreased survival (Figure 4A; median overall survival (OS), 94 vs. 15 months; Log-Rank, \( P < 0.0001 \); HR, 3.46; 95% CI, 2.12–5.64). Urinary ALCAM dichotomized around the median of 2.18 ng/ml also significantly stratified patients into high and low risk of death (Figure 4B; median OS, 62 vs. 23 months; Log-Rank, \( P = 0.048 \); HR, 1.64; 95% CI, 1.003–2.69). However, serum ALCAM dichotomized around the median of 74.88 ng/ml did not show correlation with overall survival (Figure 4C; Log-Rank, \( P = 0.929 \); HR, 1.02; 95% CI, 0.63–1.65). In order to evaluate the potential predictive power or confounding effect of each variable in our multivariable regression analysis, we computed Somers’ Dxy rank correlation between each variable and 3-year OS time considering censoring.
Table 3: Bladder cancer “shed” ALCAM cohort descriptors and frequencies

|                                | VUMC (n = 120) | UTSW (n = 64) | Comparison | Combined Cohort (n = 184) |
|--------------------------------|----------------|--------------|------------|---------------------------|
|                                | N          | Quartiles     | Mean ± SD  | N          | Quartiles     | Mean ± SD  | Test Statistic | Significance | N          | Quartiles     | Mean ± SD  |
| Age (Years)                    | 120        | 62, 69, 75   | 68 ± 10    | 63        | 63, 70, 77   | 69 ± 10    | U = 3434*     | 0.311        | 183        | 63, 69, 75   | 68 ± 10    |
| Serum ALCAM (ng/ml)            | 117        | 58.8, 74.9, 96.7 | 79.2 ± 26.3 | 29        | 53.6, 61.8, 68.6 | 69.1 ± 36.8 | U = 1096*     | 0.003*       | 146        | 57.6, 70.7, 90.5 | 77.2 ± 28.8 |
| Urine ALCAM (ng/ml)            | 111        | 0.78, 2.18, 6.18 | 4.05 ± 4.68 | 64        | 0.68, 1.35, 2.51 | 2.08 ± 2.24 | U = 2755*     | 0.013*       | 175        | 0.73, 1.72, 4.24 | 3.33 ± 4.07 |
| Urine Hemoglobin (μg/ml)       | 108        | 45, 341, 1088 | 1285 ± 2923 | 63        | 301, 503, 1055 | 1205 ± 2968 | U = 2706*     | 0.025*       | 171        | 128, 448, 1088 | 1256 ± 2931 |
| Follow-up (Months)             | 120        | 12.6, 38.1, 57.1 | 38.0 ± 57.1 | 59        | 5.0, 12.5, 29.3 | 18.3 ± 15.9 | U = 2170*     | < 0.001*     | 179        | 8.7, 26.0, 49.3 | 31.5 ± 27.3 |
| Time to Death 3 Years (Months) | 56         | 2.8, 11.1, 21.7 | 12.5 ± 10.4 | 20        | 1.7, 7.3, 17.1 | 9.5 ± 9.2  | U = 455*      | 0.219        | 76         | 2.7, 9.3, 20.9 | 11.7 ± 10.1 |
| Gender                         | 120        | 62           |            |           |              |            | χ² = 3.23*    | 0.224        | 182        |              |            |
| Female                         | 10.0%      | (12)         | 9.7%       | (6)       |              |            |              |             | 9.9%       | (18)        |
| Male                           | 90.0%      | (108)        | 90.3%      | (56)      |              |            |              |             | 90.1%      | (164)       |
| Race                           | 120        | 64           |            |           |              |            | χ² = 8.32*    | 0.014*       | 184        |              |            |
| White                          | 95.8%      | (115)        | 89.1%      | (57)      |              |            |              |             | 93.5%      | (172)       |
| Black                          | 2.5%       | (3)          | 4.7%       | (3)       |              |            |              |             | 3.3%       | (6)         |
| Other                          | 1.7%       | (2)          | 6.3%       | (4)       |              |            |              |             | 3.3%       | (6)         |
| Pathological Tumor Stage       | 120        | 63           |            |           |              |            | χ² = 5.66*    | 0.586        | 183        |              |            |
| pT0                            | 4.2%       | (5)          | 7.9%       | (5)       |              |            |              |             | 5.5%       | (10)        |
| pTa                            | 6.7%       | (8)          | 1.6%       | (1)       |              |            |              |             | 4.9%       | (9)         |
| pTis                           | 7.5%       | (9)          | 7.9%       | (5)       |              |            |              |             | 7.7%       | (14)        |
| pT1                            | 6.7%       | (8)          | 9.5%       | (6)       |              |            |              |             | 7.7%       | (14)        |
| pT2a                           | 16.7%      | (20)         | 19.0%      | (12)      |              |            |              |             | 17.5%      | (32)        |
| pT2b                           | 9.2%       | (11)         | 15.9%      | (10)      |              |            |              |             | 11.5%      | (21)        |
| pT3a                           | 25.8%      | (31)         | 17.5%      | (11)      |              |            |              |             | 23.0%      | (42)        |
| pT3b                           | 7.5%       | (9)          | 7.9%       | (5)       |              |            |              |             | 7.7%       | (14)        |
| pT4a                           | 15.8%      | (19)         | 12.7%      | (8)       |              |            |              |             | 14.8%      | (27)        |
| N Stage                         | 120        | 60           |            |           |              |            | χ² = 5.85*    | 0.088        | 180        |              |            |
| N0                             | 75.0%      | (90)         | 73.3%      | (44)      |              |            |              |             | 74.4%      | (134)       |
| N1                             | 5.0%       | (6)          | 10.0%      | (6)       |              |            |              |             | 6.7%       | (12)        |
| N2                             | 20.0%      | (24)         | 13.3%      | (8)       |              |            |              |             | 17.8%      | (32)        |
| N3                             | 0.0%       | ()           | 3.3%       | (2)       |              |            |              |             | 1.1%       | (2)         |
| Positive Lymph-node Status     | 120        | 60           |            |           |              |            | χ² = 0.06*    | 0.809        | 180        |              |            |
| 0                              | 75.0%      | (90)         | 73.3%      | (44)      |              |            |              |             | 74.4%      | (134)       |
| 1                              | 25.0%      | (30)         | 26.7%      | (16)      |              |            |              |             | 25.6%      | (46)        |
Tumor stage, positive lymph-node status, age and urine ALCAM had relatively high correlation with survival time compared to urine hemoglobin and serum ALCAM (Figure 4D). Therefore, we chose to exclude serum ALCAM from subsequent multivariable analyses but retain urine hemoglobin as an a priori defined control for urine ALCAM since there is no other way to exclude the possibility that elevated urine ALCAM could be a result of hematuria rather than direct tumor shedding.

### Urinary ALCAM and multivariable analysis for prediction of 3-year overall survival

To determine if urine ALCAM was an independent predictor of OS, multivariable Cox regression analyses were performed on this same retrospective biofluid cohort (Table 3, VUMC, n = 120). Race and gender were excluded from all multivariable analyses since the VUMC cohort is 95.8% white and 90.0% male. As stated previously, urine hemoglobin was retained in further analyses since there was concern that hematuria would be a confounder for urine ALCAM. Therefore, the baseline model (Model 1) that was used to assess the benefit of adding urine ALCAM to predict 3-year OS included age, tumor stage, positive lymph-node status, and urine hemoglobin (Table 4). As expected, age, tumor stage, and positive lymph-node status were all independent predictors of 3-year OS (Table 4; Model 1; P < 0.001, P = 0.006, P = 0.009). Importantly, after adjusting for these parameters and urinary hemoglobin, urine ALCAM was also a significant independent predictor of 3-year OS (Table 4; Model 2; P = 0.002). Of note, the multivariable prediction strength of urine ALCAM nearly matches that of tumor stage based on adjusted partial likelihood ratio Chi-square statistics (Figure 5A). By setting the age to 69 and the urine ALCAM to 2.06, we were able to calculate the interaction adjusted hazard ratios and confidence intervals for each of the parameters in the model; whereby, patients are at 1.5 times greater risk of death within 3 years following cystectomy if their urine ALCAM level is high (6.0 ng/ml) compared to low (0.75 ng/ml) (95% CI, 1.03–2.06; P = 0.002). Moreover, this effect is significantly modified by age (Table 4; Model 2, Urine ALCAM X Age, P = 0.031). To visualize this interaction, the adjusted effects of urine ALCAM were plotted at different age groups for patients with tumor stage 4, negative lymph-node status, and 341 ng/ml of urine hemoglobin (Supplementary Figure S2A). Importantly, internal validation analyses revealed that there was no significant over-fitting of the models (Supplementary Figure S3A).

The ability of urine ALCAM to improve the prediction of 3-year OS (Model 2) when compared to standard predictors alone (Model 1) was assessed by graphing reclassification plots and time-dependent receiver operating characteristics curves (ROC) based on multivariable Cox regression analyses. Reclassification plots, where the predicted risk without urine ALCAM (Model 1) is plotted against the predicted risk with urine ALCAM (Model 2), showed that the addition of urine ALCAM was effective at reclassifying patients with high and low risk of death; whereby, event points (open circles) were mainly shifted above the diagonal and non-event points (black circles) were mainly shifted below the diagonal, which is in agreement with what is expected if there is improvement in risk prediction (Supplementary Figure S2B). Additionally, the computed continuous $\frac{1}{2}$ net reclassification index (NRI)
at 1 year post-surgery is 31.5% (95% CI, 0.00–0.52; \( P = 0.05 \)), which indicates that 31.5% of patients see an improvement in risk prediction with the addition of urine ALCAM. Furthermore, the time dependent ROC curves show that over the 3 years of follow-up, there was a 3–5% increase in area under the curve (AUC) with the addition of urine ALCAM (Figure 5B). However, this is only true after the first 6 months of follow-up where it is speculated that, prior to this time, patient deaths are due to post-surgical complications and lack of recovery. There was also a 3.3% increase in Harrell’s Concordance Index (C-Index) [41] (Table 4; 75.2% vs. 78.5%). Additionally, after internal Bootstrap validation to correct for any over-fitting, the inclusion of urine ALCAM still showed a clinically meaningful improvement of 2.5% in the C-Index (Table 4; 73.5% vs. 76.0%). Importantly, urine ALCAM still remained an independent predictor of OS after accounting for additional clinical features including treatment with BCG, presence of carcinoma in situ (CIS), extent of lymph-node dissection, lymphovascular invasion, urine creatinine, and adjuvant chemotherapy (HR, 1.10; 95% CI, 1.02–1.19; \( P = 0.011 \); Table 4, Model 3).

In summary, the addition of urine ALCAM is an independent prognostic indicator and improves the prediction of post-cystectomy, 3-year overall survival of patients with BCa to a degree that is clinically relevant using the VUMC cohort.

### Validation

In order to validate the VUMC cohort results, a similar retrospective BCa cohort containing matched
serum and urine collected at time of cystectomy was obtained from University of Texas Southwestern (Table 3; UTSW, n = 64). The UTSW and the VUMC cohorts were significantly different on several parameters including urine and serum ALCAM, urine hemoglobin, follow-up time, and race (Table 3). However, urine ALCAM was still significantly elevated in the UTSW cohort compared to normal controls (10.6-fold, \( p < 0.0001 \)). The follow-up for the UTSW cohort was shorter than the VUMC cohort (Table 3; median 12.5 vs. 38.1 months) but the 3-year overall survival of the two cohorts were similar (Table 3). Since there were not enough events in the UTSW cohort for multivariable analysis (events = 20), we chose to combine the VUMC and UTSW cohorts to strengthen the generalizability of the prediction model (Table 3; events = 76).

Figure 3: Detection of shed ALCAM in biofluids of patients with bladder cancer. (A) The extracellular domain of ALCAM is cleaved from the cell surface by ADAM17 when tumor cells become invasive and can be detected in tumor-adjacent biofluids such as blood and urine. (B) ALCAM immunoblots of deglycosylated (PNGaseF) tumor cell lysates (WCL), conditioned media (CM) and urine (BCa 1 and BCa 2) probed with either antibodies to the extracellular domain (MOG/07) or intracellular domain (1G3A [23]) of ALCAM. Arrows indicate full-length (Intact ALCAM) and the cleaved ALCAM extracellular domain (ALCAM ECD). (C) ALCAM levels (ng/ml) in serum of normal controls compared to patients with BCa. (D) ALCAM levels (ng/ml) in urine of normal controls compared to patients with inflammatory conditions, cancers other than BCa, and BCa. Note segmented y-axis. UC, ulcerative colitis. SC, staghorn calculi. (E, F) Correlation of shed ALCAM in the serum (E) and urine (F) with pathological tumor stage in the VUMC shed ALCAM BCa cohort (n = 120). K-W, Kruskal-Wallis test. J-T, Jonckheere-Terpstra test for trend. Graphs display mean and 95% CI.
Again, in the combined cohort, age, tumor stage, and positive lymph-node status were all independent predictors of 3-year OS (Table 5; Model 1; P < 0.0001, P = 0.003, P < 0.001). The interaction between urine ALCAM and age remained significant (Supplementary Figure S2C and Table 5; Model 2, Urine ALCAM X Age, P = 0.038). Importantly, urine ALCAM remained a significant independent predictor of 3-year OS after adjusting for baseline parameters and the age interaction (Table 5; Model 2; adjusted HR, 1.27; 95% CI, 1.05–1.52, P = 0.001). Interaction adjusted hazard ratios and confidence intervals were calculated by setting the age to 69 and the urine ALCAM to 1.61 in the interaction term and revealed that patients have a 30% increased risk of death within 3 years following surgery if their urine ALCAM levels are high (4.05 ng/ml) compared to low (0.69 ng/ml) (95% CI 1.05–1.52, P = 0.001). Urine ALCAM still had similar prediction strength as tumor stage based on adjusted partial likelihood ratio Chi-square statistics (Figure 5C). Likewise, internal bootstrap validation revealed no significant over-fitting of model 1 and model 2 for the combined cohort (Supplementary Figure S3B).

Furthermore, similar to the VUMC cohort alone, the addition of urine ALCAM in the multivariable model tended to increase the predicted risk for event patients and decrease the predicted risk for non-event patients, thus improving the classification (Supplementary Figure S2D). In addition, the combined cohort time-dependent ROC curves show that over the 3 years of follow-up, there was a 4–5% increase in AUC with the addition of urine ALCAM (Figure 5D). Most importantly, the addition of urine ALCAM in the multi-institutional cohort still showed a clinically meaningful improvement of 2.4% in the C-Index and, after internal validation, this increase was still 1.6% (Figure 5D and Table 5; C-Index, 76.1 vs. 78.5; bootstrap validation, 75.2 vs. 76.8).

As a final analysis, we performed multiple imputation using Bayesian Bootstrap Predictive Mean Matching (PMM) on the combined cohort as a method to estimate values for missing data. After multiple imputation, urine ALCAM remained an independent predictor of 3-year OS (Table 5; adjusted HR, 1.22; 95% CI, 1.00–1.49, P = 0.018).

In summary, we show that although the histological detection of ALCAM within the tumor tissue correlates
strongly with tumor stage in BCa (Figure 2), it does not appear to be prognostic of overall survival. In contrast, urine ALCAM correlates with tumor stage and is a significant independent predictor of 3-year overall survival for patients after cystectomy. All results are summarized in Figure 6, which emphasizes the discordance between correlation with stage and correlation with outcome.

**DISCUSSION**

Although intervention can be curative for BCa patients, 50% of patients experience metastatic recurrence within two years following cystectomy [5]. Patient outcome could improve if: 1) patients with a low-grade, non-invasive BCa who are at risk of rapid progression could be identified for earlier radical surgical intervention and 2) patients with high-grade and/or invasive BCa at risk of metastatic recurrence could be identified for more aggressive intervention such as neo-adjvant or adjuvant chemotherapy. Prognostic biomarkers can aid in identification of such high-risk patients. Urinary biomarkers have additional clinical value in that they provide a longitudinal and non-invasive means to monitor tumor progression, recurrence and treatment response. Molecular products that are mechanistically involved in or directly result from cell motility make particularly attractive biomarkers because tumor cell migration is a central driver of malignant progression and metastatic dissemination [42]. These molecular motility markers could predict or detect disease progression before overt clinical manifestation. ALCAM forms adhesive interactions between neighboring epithelial cells but cohesion is disrupted by membrane proximal, proteolytic cleavage and release of the ALCAM ectodomain from

### Table 5: Assessment of urinary “shed” ALCAM as a predictor in a multivariable Cox regression analysis of 3-year overall survival in the combined VUMC and UTSW bladder cancer cohort

| Variable                  | Hazard Ratio | 95.0% CI   | Significance | Bootstrap Significance |
|---------------------------|--------------|------------|--------------|-----------------------|
| **Model 1**               |              |            |              |                       |
| Age (Years)               | 1.05<sup>c</sup> | 1.03–1.08  | < 0.0001     | 0.001                 |
| Tumor Stage               | 1.25<sup>c</sup> | 1.08–1.45  | 0.003        | 0.001                 |
| Lymph-node Positive       | 2.95<sup>c</sup> | 1.64–5.28  | < 0.001      | 0.002                 |
| Urine Hemoglobin (μg/ml)  | 1.00<sup>c</sup> | 0.99–1.00  | 0.073        | 0.072                 |
| **C-Index**               | 76.1%        | 70.7–81.4  | 75.2<sup>*</sup> |
| **Model 2**               |              |            |              |                       |
| Age (Years)               | 1.58<sup>b</sup> | 1.08–2.34  | < 0.0001     | 0.001                 |
| Tumor Stage               | 1.75<sup>c</sup> | 1.28–2.37  | < 0.001      | 0.002                 |
| Lymph-node Positive       | 2.69<sup>c</sup> | 1.47–4.92  | 0.001        | 0.002                 |
| Urine Hemoglobin (μg/ml)  | 1.04<sup>c</sup> | 0.97–1.12  | 0.278        | 0.463                 |
| Urine ALCAM (ng/ml)       | 1.27<sup>c</sup> | 1.05–1.52  | 0.001        | 0.005                 |
| Urine ALCAM X Age*        |              |            |              |                       |
| **C-Index**               | 78.5%        | 73.4–83.7  | 76.8<sup>*</sup> |
| **Multiple Imputation**   |              |            |              |                       |
| Age (Years)               | 1.52<sup>c</sup> | 1.07–2.17  | 0.0002       |                       |
| Tumor Stage               | 2.34<sup>c</sup> | 1.48–3.69  | 0.0003       |                       |
| Lymph-node (N Stage)      | 1.66<sup>c</sup> | 1.24–2.21  | 0.0006       |                       |
| Urine Hemoglobin (μg/ml)  | 1.04<sup>c</sup> | 0.95–1.13  | 0.408        |                       |
| Urine ALCAM (ng/ml)       | 1.22<sup>c</sup> | 1.00–1.49  | 0.018        |                       |
| Urine ALCAM X Age*        |              |            |              |                       |

Assessment of urinary shed ALCAM as a predictor of 3-year overall survival by multivariable Cox regression analysis in the combined VUMC and UTSW cohort. CI, confidence interval. Bootstrap significance is two-tailed with 1000 iterations and a Mersenne twister of 2,000,000. Hazard ratio is the adjusted hazard ratio for every 1 unit increase, urine ALCAM at 1.61 ng/ml, but 8 years older, 2 tumor stage increase, 0.90 μg/ml higher urine hemoglobin, and 69 year old with a 3.36 ng/ml increase in urine ALCAM. *, Interaction term. C-Index, Harrell’s Concordance Index [41]. Ψ, internal validation of the C-Index, confidence interval calculations not available. Multivariable Cox regression analysis with Model 2 in the combined VUMC and UTSW cohort after replacement of missing data by multiple imputation via Bayesian Bootstrap Predictive Mean Matching (PMM) [51, 52]. Hazard ratio is the adjusted hazard ratio for urine ALCAM at 1.72 ng/ml, but 12 years older, 3 tumor stage increase, 1 lymph-node stage (N Stage, 0–3) increase, 0.96 μg/ml higher urine hemoglobin, and 69 year old with a 3.50 ng/ml increase in urine ALCAM.
mobile tumor cells [20, 21]. Therefore, ALCAM shedding is not specific to bladder cancer. Rather, the shed extracellular domain of ALCAM is a marker of invasive and metastatic disease and, thus, has the potential to be a clinically relevant prognostic biomarker in many epithelial cancers.

In agreement with our results, two recent publications looking at the correlation of ALCAM tissue expression with stage and outcome in breast cancer also reveal a loss in detectable levels of ALCAM by immunohistochemistry as tumors progress [43, 44]. This is consistent with our hypothesis that the loss of detection is due to increases in ALCAM shedding as tumors become invasive. Indeed, another group has shown in a diagnostic study that patients with breast cancer have elevated serum levels of ALCAM [45]. However, it has yet to be demonstrated that ALCAM shedding correlates with stage or outcome in breast cancer. We previously demonstrated in colorectal cancer that reduced detection of the ALCAM extracellular domain in tumor tissue is due to ALCAM shedding which, in turn, corresponds with poor patient outcome [23]. Those observations suggested that detection of shed ALCAM in adjacent biofluids could predict disease progression. This hypothesis was tested in our evaluation of urinary ALCAM from BCa patients. Indeed, there is a significant loss of intra-tumoral ALCAM during invasive transformation (Figure 2), while urinary ALCAM levels rise and correlate with poor outcome (Figures 3 and 4) (Figure 6). Further statistical interrogation provides evidence that urinary ALCAM is a significant independent predictor of overall survival after adjusting for age, tumor stage, positive lymph-node status, and urinary hemoglobin (Table 4) and improves accuracy of prediction (i.e. discrimination) by 3.3% (Figure 5). Furthermore, this observation was validated in a combined multi-institutional cohort (Figure 5 and Table 5).

Although our main hypothesis is in regards to prognosis, it is interesting to note that in the current study, serum ALCAM has a diagnostic accuracy, an area under the receiver operating characteristics curve, of 0.75 ($p = 0.002, 95%CI 0.64–0.85$) and urine ALCAM a 0.90 ($p < 0.0001, 95%CI 0.85–0.94$) in distinguishing all-stage bladder from normal and inflammatory controls combined. As a comparison, cystoscopy and cytology together are 80–99% accurate at diagnosing BCa and are more than commonplace in the clinic. Therefore, it is unlikely that shed ALCAM would provide any added diagnostic benefit in advanced, muscle-invasive bladder cancer. It would,
however, be interesting to evaluate the diagnostic benefit of adding urine ALCAM to cytology in early-stage disease where cytology is much less accurate.

Our initial analysis was restricted to retrospective cohort studies based on the need for long-term follow-up in prognostication. While the retrospective nature of this study poses limitations in regards to confidence in extrapolation to larger populations due to biases such as lack of racial and gender diversity, incomplete recurrence data, and confounding associated with reporting, sample collection, clinicians, and/or institutional practices, we have removed some potential biases by combining two independent cohorts collected at VUMC and UTSW. Furthermore, we have applied rigorous bootstrap validation methods and a team of biostatisticians has independently validated all statistical analyses. Interestingly, in a small subset analysis of the VUMC retrospective cohort \( (n = 40) \), urine ALCAM was an even stronger predictor of metastatic recurrence \( (HR = 10.4) \), which should be expected for a molecule that is indicative of invasive disease. Unfortunately, recurrence data and/or disease specific survival was not available for a majority of the patients. Larger multi-institution and multi-country prospective cohort studies are ongoing to validate the prognostic utility of urinary ALCAM in BCa and will require 3 years of enrollment and an additional 3–5 years of follow-up. These prospective studies encompass repeated collection of biofluids and tissues over the course of progression, surgery, and (neo)adjuvant treatment, and will allow the tracking of cancer-specific outcome measures such as progression-free survival, treatment response, metastasis, and disease-specific survival.

The correlation between ALCAM shedding and patient outcome suggests that this process contributes to disease progression. Thus, therapeutic targeting of this process could limit disease progression and improve patient outcome. The promiscuity and critical roles of the sheddase, ADAM17, limit the utility of targeting the protease directly. However, the proteolytic fragments released by the shedding event are hypothesized to convey their own biological activity. Studies investigating how these fragments alter the tumor phenotype and how that mechanism can be targeted for intervention are currently ongoing.

In summary, we provide evidence that shed ALCAM is an independent prognostic biomarker for overall survival in BCa. Our findings also suggest potential utility of shed ALCAM in longitudinal, post-diagnostic surveillance and monitoring of treatment response. Detection of shed ALCAM in tumor-adjacent fluids makes it a promising non-invasive and cost-effective biomarker in BCa as well as other cancers with tumor-associated biofluids. We further speculate that, although urine ALCAM is the predictor in non-metastatic BCa, ALCAM shed into the blood will have prognostic relevance in patients with metastatic disease. Furthermore, since ALCAM contributes mechanistically to cell migration and metastasis, our findings provide evidence that the molecular status of a migratory mechanism can report on the clinical risk of disease progression. Finally, findings

---

**Figure 6: Summary of the multi-level approach for analysis of ALCAM in bladder cancer.** In the current study, we evaluate the prognostic significance of ALCAM mRNA, protein, and shedding in regard to overall survival in bladder cancer. The urothelium expresses an abundance of ALCAM. ALCAM is then cleaved from the cell surface by the protease ADAM17 during invasive progression of cancer. ALCAM shed from malignant urothelium should be detectable and elevated in adjacent fluids such as serum and urine. Our data supports the hypothesis that ALCAM shedding, which is a functional read-out of tumor cell migration and thus, invasion and metastasis, has greater prognostic value than its expression.
from this study suggest that focusing on protein function rather than expression alone has the potential to aid in biomarker discovery, development and implementation.

MATERIALS AND METHODS

Specimen collection

All specimen collections were approved by the Vanderbilt (VUMC) and University of Texas Southwestern (UTSW) Institutional Review Boards (IRB) and patient confidentiality was protected according to the U.S. Health Insurance Portability and Accountability Act (HIPAA). All fluids were stored at -80°C. Tissues were processed as standard diagnostic blocks and stored in the VUMC tissue library.

Study populations

ALCAM mRNA cohort

NCBI Gene Expression Omnibus (GEO, GSE31684) [32] was used to analyze ALCAM mRNA expression from excised cystectomy tumor tissue (probes 201951_at and 201952_at) in BCa and included 93 patients, representing stages pTa to pT4, who underwent radical cystectomy at Memorial Sloan-Kettering Cancer Center between 1993 and 2004. Median age of patients was 69.1 years, 73% were male, median follow-up was 32 months, and incidence of death was 70%. In addition, 3 other BCa GEO datasets were utilized to compare ALCAM mRNA expression in non-muscle invasive to muscle invasive disease (GSE48276, GSE13507, GSE3167) [29–31].

ALCAM expression bladder cancer TMA cohort

Histological analysis of ALCAM protein expression was performed on a tissue microarray (TMA) from a retrospective cohort of patients undergoing radical cystectomy at VUMC from 2000–2010 for high-grade bladder cancer (301 patients, 657 total cores). The TMA was constructed from formalin-fixed, paraffin-embedded cystectomy diagnostic tissue blocks. Each patient contributed between 1 and 6 cores to the array, with matched core designations of adjacent normal, superficial (pTa and pTis/Cis) and invasive (≥ pT1). Immunofluorescence staining for ALCAM was performed and correlation with overall survival was analyzed for those patients with a designated “invasive” core (n = 198). Correlation of ALCAM expression with core pathology stage was performed on all unique cores (n = 481) as described in statistical methods. The mean immunofluorescence calculation was used when a core designation was represented more than once for a single patient, such as multiple normal cores, which is why there were only 481 unique cores of the 651 total cores.

Shed ALCAM bladder cancer cohorts (VUMC)

The analysis of shed ALCAM in serum and urine, at time of surgery, was performed on a retrospective cohort of patients with high-grade bladder cancer undergoing radical cystectomy at VUMC from 2001–2006, which included pathological stages from pT0 to pT4 and excluded patients who had received neoadjuvant chemotherapy (n = 120).

Urine control cohorts

The following age-matched, control clean-catch or catheter-derived urine specimens were collected at VUMC by the Cooperative Human Tissue Network: 1) Non-cancer control urines (Normal Controls) from patients with no history or current diagnosis of cancer undergoing non-urologic surgeries including cardiac bypass, gastric bypass, thyroidectomy, esophagomyotomy, knee replacement, and hernia repair, 2) Inflammation control urines (Inflammation) from patients with rectovaginal fistula, colorectal enteritis and ulceration, gallbladder polyploid cholesterolosis, endometriosis, atherosclerosis, ulcerative colitis, uterine fibroids, urethral stricture, and staghorn calculus, 3) Non-urologic cancer control urines (General Cancer) from patients with prostate, pancreatic, neuroendocrine, renal, and colorectal cancers.

Non-cancer serum control cohort

Serum from age-matched, non-cancer patients was collected from discarded vitamin D clinical tests in the Vanderbilt Clinical Chemistry laboratory.

Shed ALCAM bladder cancer cohort (UTSW)

For validation of urine ALCAM as a prognostic biomarker, our VUMC cohort was combined with a randomly selected retrospective cohort of patients with high-grade bladder cancer undergoing radical cystectomy at UTSW from 2005–2013, which included pathological stages from pT0 to pT4 (n = 64). Biofluids were collected at time of surgery.

Immunofluorescence

Immunofluorescence (IF) was performed on the tissue microarray described above. Sections (5µm) were deparaffinized and rehydrated. Antigen retrieval was performed by pressure cooker in citrate buffer (pH 6.0) and sections blocked in 20% Aquablock (East Coast Biologics) plus 0.05% Tween-20. IF was performed with primary antibodies mouse anti-ALCAM (MOG/07; 1:100; Novocastra™ Leica Biosystems), rabbit anti-Ki67 (Clone SP6; 1:500; Thermo Scientific), and Hoechst 33342 as well as, secondary antibodies Alexa-546 goat anti-rabbit and Alexa-647 goat anti-mouse (1:500; LifeTechnologies). Collagen was stained with Alexa 488-conjugated...
CNA35 (gift from Erin Rericha, Vanderbilt) [46, 47]. IF slides were mounted in ProLong Gold Antifade reagent (Invitrogen). Fluorescence intensity and thresholded area were quantified in the epithelium in each TMA core with an Image J-based batch macro. Collagen staining was used to distinguish between the epithelial, stromal and muscular compartments. Hoechst was used to define the nuclear compartment while Ki67 marked proliferating cells. Percent thresholded area of ALCAM was subsequently used for analysis.

**Urine ALCAM normalization**

In order to assess the influence of hydration, proteinuria, and hematuria on urinary ALCAM levels, we initially aimed to include all these parameters in the multivariable models. Urinary total protein (Thermo Scientific, BCA, Cat# 23227), urinary creatinine (Enzo Life Sciences, Cat# 937–001), urinary specific gravity (Siemens Medical Solutions Diagnostics, Multistix® 8 SG, Cat# 2164) and urinary hemoglobin (Sigma-Aldrich, Drabkin’s Reagent, Cat# D5941) were all analyzed in a random subset of the VUMC cohort specimens. Unfortunately, the presence of urea made BCA analysis for total protein in urine unreliable and the limited dynamic range of specific gravity did not provide sufficient means to normalize. Urine creatinine neither added predictive value to the model nor altered the strength of urine ALCAM to predict overall survival. Therefore, only urine hemoglobin was considered in the final prediction model and analyzed in both the VUMC and UTSW cohorts.

**ALCAM immunoblotting**

Immunoblotting for shed ALCAM was performed on urine from two patients with bladder cancer, the whole cell lysates from the fibrosarcoma cell line HT1080 and the bladder cancer cell line UMUC-3 as well as, UMUC-3 24-hour serum-free conditioned media. Urine and conditioned media were first precipitated with ice-cold acetone (1:4) at -20°C overnight, pelleted at 15,000 rpm for 15 minutes at 4°C, supernatant decanted and protein pellet air-dried for 15 minutes at room temperature. The protein pellet was then resuspended in lysis buffer (1.0% TritonX-100 in PBS) and sonicated at 37°C for 15 minutes. Next, all samples were deglycosylated using a PNGaseF kit according to the manufacturer’s instructions (P0704s; New England Biolabs). Deglycosylated samples were then run on two identical 12% polyacrylamide gels for 30 minutes at 80 volts then 1.5 hours at 120 volts, transferred to a methanol-activated PVDF membrane in transfer buffer (25mM Tris, 192mM glycine, 20% methanol) for 2 hours at 100 volts, and blocked overnight with 5% milk. One blot was probed with a mouse monoclonal antibody against the extracellular domain (MOG/07; 1:1000; Abcam) and the other with our previously characterized in-house mouse monoclonal antibody against the intracellular domain (1G3A; 1:2000) [23] overnight at 4°C and then incubated with HRP-conjugated goat anti-mouse antibody (1:2500; Abcam) for 1 hour at room temperature. Blots were developed with West Fempta Enhanced Chemiluminescence reagent for 5 minutes and photons read for a total of 15 minutes in a digital light box (G:BOX; Syngene).

**ALCAM enzyme-linked immunosorbent assay**

Serum and urine were analyzed by ALCAM ELISA according to the manufacturer’s protocol (R&D Systems). All samples were analyzed in duplicate at dilutions (Urine: 4–8 fold; Serum: 50–80 fold) that matched the dynamic range of the assay (0.05–4.00 ng/ml).

**Statistical analysis**

Statistical analyses were performed at a two-tailed significance of 0.05. Descriptive statistics such as mean and 95% confidence interval (CI) for ALCAM mRNA expression among different cohorts were graphed. Kruskal-Wallis and/or Wilcoxon rank-sum (Mann-Whitney U) tests were performed for comparing ALCAM mRNA level and ALCAM biofluid concentrations between independent groups such as different stages or cohorts. Jonckheere-Terpstra tests for non-independent groups were also used to assess trends of mRNA levels, protein levels or shed ALCAM concentrations with increasing tumor stage. To evaluate the association of ALCAM protein expression with core stage in the BCa TMA cohort, generalized estimating equations (GEE) ordinal logistic regression was used in order to account for the representation of multiple core stages for each patient (non-independent samples). Kendall’s τ rank correlation was also calculated. Kaplan-Meier curves and log-rank tests were utilized for univariable survival analysis.

To assess the value of urine ALCAM as a biomarker, multivariable Cox regression analyses were performed using the VUMC and UTSW cohort data to predict overall survival (OS) of bladder cancer patients after cystectomy. OS time was defined as time from the date of cystectomy to date of death or last follow-up and was restricted to 3 years. The multivariable models were determined a priori based on each covariate’s potential to confound or modify the association between shed ALCAM and survival as well as data availability. Urine hemoglobin was included in the model to adjust for bleeding in the urine (hematuria) and account for any contamination of urine with serum ALCAM. In the models, tumor stage, age, hemoglobin and urine ALCAM were modeled as continuous variables and lymph-node status as a binary variable. An interaction term between age and urine ALCAM was also included when the urine ALCAM was in the model. The models were internally validated using .632+ [48] bootstrapping
and calibration accuracy for 2- and 3-year survival was also estimated using bootstrapping. The model results were also compared with those fitted using multiple imputed data. Time-dependent receiver operating characteristics (ROC) curves [49], Harrell’s Concordance Index [41] and predicted risk scores were compared between models with and without urine ALCAM to assess the added value of urine ALCAM for discrimination in predicting patient survival. In addition, the continuous net reclassification index (NRI) was calculated using Uno’s package [40].

Statistical analyses and graphing were performed with SPSS (IBM), GraphPad Prism (GraphPad Software, Inc.) and R V 3.1.0 (http://www.R-project.org) [50] and several R packages, including “Hmisc”, “rms”, “survivalROC” and “survIDINRI”. Bootstrap validation was performed via SPSS with a two-tailed significance, 1000 iterations and a Mersenne twister of 2,000,000 as well as in R as already described.

Impact

Beyond the initiating genetic event, cancer progression and metastasis is primarily controlled by alterations in the proteome. The cell migration machinery and its functional products not only contribute mechanistically to metastatic dissemination but also have the potential to serve as markers of invasive disease. While ALCAM has been postulated as such a biomarker, multiple studies have yielded contradicting results. The current study utilizes gene expression, immunofluorescence staining, and ELISA analysis of serum and urine to demonstrate that ALCAM shedding, but not expression, corresponds to patient outcome in bladder cancer. Furthermore, this multi-institutional cohort analysis reveals that shed urinary ALCAM is an independent prognostic indicator of overall survival in patients undergoing cystectomy. We are the first to suggest that urinary ALCAM can aid in the identification of high-risk patients and in directing intervention. This data highlights the significance of focusing on protein function and post-translational events in identification of novel biomarkers.

ACKNOWLEDGMENTS

We would like to acknowledge our clinical collaborators Igor Puzanov and Christina Derleth. We gratefully acknowledge the gift of the collagen binding peptide CNA35 from Erin Rericha. A special thanks to the laboratory of Bob Matusik including his technician, Manik Paul and formal postdoctoral fellow, David DeGraff. We gratefully acknowledge Chaochen You for maintenance of the urology database. We would also like to acknowledge Joseph Roland in the Vanderbilt Epithelial Biology CORE as well as Alison Woodworth and Sherrie Stafford in the Vanderbilt Clinical Chemistry laboratory. Many thanks to Kerry Wiles, Marie Jacobovitz, Ellen Heimann-Nichols, and Dana Reeves in Vanderbilt CHTN. We acknowledge additional current and former members of the Zijlstra laboratory including Celestial Jones-Paris, Amanda Hansen, Trenis Palmer, Katherine Hebron, Adel Eskaros, and Chase Taylor. Lastly, we would like to acknowledge the patients who donated tissue for their contribution to the future advancement of science.

CONFLICTS OF INTEREST

The authors have no current competing interests to disclose. However, Vanderbilt University Medical Center has filed, but has not yet been awarded, a patent on the use of shed ALCAM as a biomarker for a variety of cancers on behalf of Andries Zijlstra, Shanna Arnold, and Amanda Hansen.

GRANT SUPPORT

This work was supported by the National Institutes of Health for AZ (R01-CA143081 and P01-CA040035), SAE (VCORCDP K12-CA090625 and CTSA UL1-TR000445), PC (P30-DK079341) and YL (R01-CA151489 and NCRR 5 UL1-RR24982), and the Department of Veterans Affairs SAE (VA CDA IK2BX002498). AZ also received support from Alberta Innovates Health Solutions (AIHS).

Authors’ contributions

SAE, PC and AZ were responsible for the study concept and design as well as manuscript preparation. SAE performed specimen processing and analysis, database construction and maintenance, and all data/statistical analyses. LD, PS and YS provided statistical support and validated the statistical analyses. HL and AS contributed to the immunofluorescence quantitation. TK performed the immunofluorescence staining. PC contributed to the VUMC cohort selection and collection. PK contributed to the database development and management. JW performed the immunoblotting of the urine. OF and JC provided pathology support. YL and AH were responsible for the UTSW cohort selection, collection and database management.

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–386.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5–29.

3. Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larre S, Di Stasi S, Van Rhijn B, Witjes AJ, Grottenhuis AJ, Kiemeney LA, Colombo R, et al. Prognostic Factors and Risk Groups in T1G3-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients. Eur Urol. 2014.

4. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009; 56:430–442.

5. Yafi FA, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf J-B, Bell D, Saad F, et al. Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int. 2012; 110:1317–1323.

6. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003; 21:1315–1330.

7. Collaboration ABCAM-a. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005; 48:202–205- discussion 205–206.

8. Raghavan D, Burgess E, Gaston KE, Haake MR, Riggs SB. Neoadjuvant and adjuvant chemotherapy approaches for invasive bladder cancer. Semin Oncol. 2012; 39:588–597.

9. Smith ZL, Guzzo TJ. Urinary markers for bladder cancer. F1000Prime Reports. 2013; 5:21.

10. Eissa S, Kassim S, El-Ahmady O. Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers. Curr Opin Obstet Gynecol. 2003; 15:395–403.

11. Kim W-J, Bae S-C. Molecular biomarkers in urothelial bladder cancer. Cancer Sci. 2008; 99:646–652.

12. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, et al. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell. 2014; 158:929–944.

13. Palmer TD, Ashby WJ, Lewis JD, Zijlstra A. Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev. 2011; 63:568–581.

14. Masedunskas A, King JA, Tan F, Cochran R, Stevens T, Sviridov D, Ofori-Acquah SF. Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration. FEBS Lett. 2006; 580:2637–2645.

15. Smith JR, Chips TJ, Ilias H, Pan Y, Appukuttan B. Expression and regulation of activated leukocyte cell adhesion molecule in human retinal vascular endothelial cells. Exp Eye Res. 2012; 104:89–93.

16. Abdi SM, Saifullah MK, Zafiropulos MD, Kaput C, Bowen MA, Cotton C, Singer NG. CD166 expression, characterization, and localization in salivary epithelium: implications for function during sialoadenitis. J Clin Immunol. 2006; 26:12–21.

17. Fraboulet S, Kavvadia K, Pourquie O, Sharpe PT, Mitsiadias TA. BEN/DM-GRASP/SC1 expression during mouse facial development: differential expression and regulation in molars and incisors. Gene Expr Patterns. 2003; 3:255–259.

18. Jannin KM, Stipp CS, Weiner JA. ALCAM regulates motility, invasiveness, and adherens junction formation in uveal melanoma cells. PLoS One. 2012; 7:e39330.

19. Weidle UH, Eggle D, Klostermann S, Swart GW. ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics. 2010; 7:231–243.

20. Rosso O, Piazza T, Bongarzone I, Rossello A, MezzanzanicaD, Canevari S, Orongo AM, Puppo A, Ferrini S, Fabbì M. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res. 2007; 5:1246–1253.

21. Bech-Serra JJ, Santiago-Josefat B, Esselens C, Saftig P, Baselga J, Arribas J, Canals F. Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis. Mol Cell Biol. 2006; 26:5086–5095.

22. Hansen AG, Arnold SA, Jiang M, Palmer TD, Ketova T, Merkel A, Pickup M, Samaras S, Shyr Y, Moses HL, Hayward SW, Sterling JA, Zijlstra A. ALCAM/CD166 is a TGF-beta-responsive marker and functional regulator of prostate cancer metastasis to bone. Cancer Res. 2014; 74:1404–1415.

23. Hansen AG, Freeman TJ, Arnold SA, Starchenko A, Jones-Paris CR, Gilger MA, Washington MK, Fan KH, Shyr Y, Beauchamp RD, Zijlstra A. Elevated ALCAM Sheding in Colorectal Cancer Correlates with Poor Patient Outcome. Cancer Res. 2013; 73:2955–2964.

24. Carbotti G, Orenço AM, Mezzanzanica D, Bagnoli M, Brizzolara A, Emionite L, Puppo A, Centurionì MG, Bruzzone M, Marroni P, Rossello A, Canevari S, Ferrini S, et al. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors. Int J Cancer. 2012.

25. Witzel I, Schröder C, Müller V, Zander H, Tachezy M, Meinke-Pfaffenberger P. ALCAM regulates motility and invasion of breast cancer patients and implications for prognosis. Oncology. 2012; 82:305–319.

26. Ihnen M, Jänicke F, Milde-Langosch K. Relevance of activated leukocyte cell adhesion molecule in human retinal vascular endothelial cells. Exp Eye Res. 2014; 120:449–458.
adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients. BMC Cancer. 2012; 12:140.

27. Tachezy M, Effenberger K, Zander H, Minner S, Gebauer F, Vashist YK, Sauter G, Pantel K, Izbicki JR, Bockhorn M. ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer. 2012; 131:396–405.

28. Tachezy M, Zander H, Marx AH, Stahl PR, Gebauer F, Izbicki JR, Bockhorn M. ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One. 2012; 7:e39018.

29. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014; 25:152–165.

30. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, Orntoft TF. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 2004; 64:4040–4048.

31. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ, Bae SC. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010; 9:3.

32. Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH, Michor F. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 2012; 18:1323–1333.

33. Ofori-Acquah SF, King J, Voelkel N, Schaphorst KL, Stevens T. Heterogeneity of barrier function in the lung reflects diversity in endothelial cell junctions. Microvasc Res. 2008; 75:391–402.

34. Chaker S, Kak I, Macmillan C, Ralhan R, Walfish PG. Activated leukocyte cell adhesion molecule (ALCAM/CD166) is a marker for thyroid cancer aggressiveness and disease-free survival. Thyroid. 2012.

35. Ishiguro F, Murakami H, Mizuno T, Fujii M, Kondo Y, Usami N, Taniguchi T, Yokoi K, Osada H, Sekido Y. Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer. J Surg Res. 2013; 179:24–32.

36. Minner S, Kraetzig F, Tachezy M, Kilic E, Graefen M, Wilczak W, Bokemeyer C, Huland H, Sauter G, Schlom M. Low-activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. Hum Pathol. 2011; 42:1946–1952.

37. Tachezy M, Zander H, Gebauer F, Marx A, Kaifi JT, Izbicki JR, Bockhorn M. Activated leukocyte cell adhesion molecule (CD166)–its prognostic power for colorectal cancer patients. J Surg Res. 2012; 177:e15–20.

38. Tachezy M, Zander H, Marx AH, Gebauer F, Rawnaq T, Kaifi JT, Sauter G, Izbicki JR, Bockhorn M. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients. J Surg Res. 2011; 170:226–232.

39. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. (New York: Springer).2001.

40. Uno H, Tian L, Cai T, Kohane IS, Wei LJS. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat Med. 2013; 32:2430–2442.

41. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15:361–387.

42. Palmer TD, Ashby WJ, Lewis JD, Zijlstra A. Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev. 2011; 63:568–581.

43. Burandt E, Bari Noubar T, Lebeau A, Minner S, Burdelski C, Janicke F, Muller V, Terracciano L, Simon R, Sauter G, Wilczak W, Lebok P. Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: A TMA-based immunohistochemical study on 2,197 breast cancer patients. Oncol Rep. 2014.

44. Tan F, Mosunjac M, Adams AL, Adade B, Taye O, Hu Y, Rizzo M, Ofori-Acquah SF. Enhanced down-regulation of ALCAM/CD166 in African-American Breast Cancer. BMC Cancer. 2014; 14:715.

45. Kulasingam V, Zheng Y, Soosaipillai A, Leon A, Gion M, Diamandis E. Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer. Int J Cancer. 2009.

46. Boerboom RA, Krahm KN, Megens RT, van Zandvoort MA, Merkx M, Bonten CV. High resolution imaging of collagen organisation and synthesis using a versatile collagen specific probe. J Struct Biol. 2011; 170:226–232.

47. Boerboom RA, Krahm KN, Megens RT, van Zandvoort MA, Merkx M. Fluorescently labeled collagen binding proteins allow specific visualization of collagen in tissues and live cell culture. Anal Biochem. 2006; 350:177–185.

48. Efron B, Tibshirani R. Improvements on cross-validation: The .632+ bootstrap method. J Am Stat Assoc. 1997; 92:548–560.

49. Lehmkuhl A, Zenz T, Wohlgemuth P, Ammer H, Zilbermann S, Hohenberger W, Haendler B, Wilke H. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 1999; 55:1375–1385.

50. R Development Core Team. R: A language and environment for statistical computing. 2008; https://www.r-project.org/.
51. Marshall A, Altman DG, Holder RL. Comparison of imputation methods for handling missing covariate data when fitting a Cox proportional hazards model: a resampling study. BMC Med Res Methodol. 2010; 10:112.

52. Marshall A, Altman DG, Royston P, Holder RL. Comparison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study. BMC Med Res Methodol. 2010; 10:7.